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Methods

Background
Cancers like glioblastoma remain unmanageable for most
patients and even with the current optimal treatment offered,
survival rates are far too low. Fortunately, several preclinical
and clinical studies indicate that oncolytic viruses have the
potential to effectively eradicate cancers. Data from one such
clinical trial, DNX-240, a recently completed first-in-human
Phase I clinical trial using Delta-24-RGD to treat recurrent
glioblastoma (NCT00805376) demonstrated that the oncolytic
virus successfully excites an antitumor immune response.The
oncolytic adenovirus Delta-24-RGD includes a deletion in the
E1A region that confers tumor-selective infectivity and an RGD
peptide motif insertion that improves infective power.

The genome of Delta-24-RGDOX-DH was amplified by PCR and
sequenced to ensure the viral construct incorporated the appropriate genetic
modifications. Next, the expression of murine OX40L in the membrane of
infected cells was assessed using western blot and flow cytometry and the
expression of other viral proteins by infected cells was analyzed by western
blotting. The presence of immune cell populations in tumor-bearing mice was
measured between treatment groups with flow cytometry. Afterwards, the
oncolytic effects of oncolytic viruses were tested by infecting A549 human lung
carcinoma cells and measuring cell counts over time. Then, studies of mice were
conducted to compare the therapeutic effect of viruses on 4T1-derived breast
tumors compared to a mock infection.

Results
Figure 7. With the immune cell population analysis in the tumor, there is a trend
toward an activation of anti-tumor immunity with an increase in CD8+ T cells, Natural
Killer cells, and Myeloid-Derived Suppressor Cells, and a decrease in CD4+ T cells
and Regulatory T cells.

Figure 1. Maximum Change in Tumor Size Among
Recurrent Malignant Glioma Patients Treated with
1 Dose of Delta-24-RGD (Lang e/ al., JCO, 2018)
For the majority of patients, the size of their tumors
decreased markedly.

Hypothesis

Figure 9 (right). Kaplan-Meier Graph Depicting Survival in
Mice with Breast Cancer Treated with Virus vs. Mock
Virus
Shows that mice treated with Delta-24-RGDOX survived
significantly longer than the mock treatment mice (p=0.0070).

Figure 2. Patient Survival in
Months According to Treatment
Dose
5 patients survived past 3 years

Figures 3 (Left), 4 (Right). Delta-24-RGDOX-DH Sequences of Note
Amplifying (Figure 2) and sequencing (Figure 3) Delta-24-RGDOX-DH DNA
indicates the viral construct integrates every necessary edit to form a functional,
immune-stimulating oncolytic virus.

We hypothesize that the anti-tumor effect might be amplified
by the expression of positive immune checkpoints.
To test this, we incorporated a costimulatory ligand (OX40L)
after the fiber region to maximize T-cell activity, which generated
our new oncolytic virus Delta-24-RGDOX-DH.

Conclusions
●

●

●
Figure 1. Schematic Illustration of Intended Modifications to the
Delta-24-RGDOX-DH viral genome
Delta-24-RGDOX-DH’s modifications to the adenovirus genome are: 1. a 24bp
deletion in E1A region to allow tumor-selective infectivity, 2. an RGD-4C peptide
motif insertion in the Fiber region to boost infectivity of cancer cells. 3. the
addition of the sequence coding for the costimulatory ligand OX40 after the Fiber
region to prompt the immune system to target infected cancer cells
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Figure 8. Cell Viability Assay
There was an 85% reduction in cell viability by Day 4 in cells infected with
Delta-24-RGDOX-DH compared to cells infected with PBS.
(2-way ANOVA, p=0.0015)

Figure 5. Western Blot Testing Infection-Competency and OX40L
Expression on A549 Cell Surface
Only cells infected with an oncolytic virus expressed the proteins Hexon
and Fiber which indicate infection-capability. Additionally, the cells infected
with the oncolytic viruses that incorporate a costimulatory ligand
sequence expressed OX40L on their cell surface.

Figure 6. Flow Cytometry of Infected A549 Cells Showing Appropriate
Expression of OX40L on Cell Surface
Virally-infected A549 lung carcinoma cells (5MOI) collected at 48 hours
present OX40L only once infected with Delta-24-RGDOX-DH
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The Delta-24-RGDOX-DH genome had all the desired genomic
alterations that give it the ability to selectively infiltrate and lyse
cancer cells, demonstrating reliability in production and utility.
Experiments showed that Delta-24-RGDOX-DH produced a
substantial infection in vitro and in vivo with effective cancer cell
lysis and increased activation of the immune system in
tumor-bearing mice.
Experiments also showed the modified virus produces the
necessary costimulatory ligand to maximize infection and
reinvigorate immune lymphocytes.
Delta-24-RGDOX-DH shows promising signs of efficacy as an
anti-cancer therapy, so our data should propel the development of
clinical trials with Delta-24-RGDOX-DH for patients with high-grade
glioma, or other aggressive types of cancer.
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